| Post date: 2021/03/25 |
Numerous oncogenic and oncolytic viruses (HBV, HCV, HPV, EBV, HIV, Coxsackievirus, reovirus, vaccinia virus, adenovirus) are known to cause and regress various cancer types. Whether SARS-CoV-2 infection could cause or increase the risk of cancer has been of much debate!
COVID-19 by itself remains biologically novel and not much is known about the role of novel coronavirus SARS-CoV-2 in cancer. Similar to other severe acute respiratory outbreaks (SARS-CoV, MERS-CoV), comorbidities such as hypertension and malignancy predispose COVID-19-positive patients to adverse clinical outcomes. Nevertheless, there exists no clear evidence that SARS-CoV-2 is causative, related to, or modulates cancer pathobiology! In this regard, further research is needed to improve the understanding of the biology of SARS-CoV-2 virus, its molecular connection to cancer, and the temporal features of SARS-CoV‐2-induced inflammatory response in relation to the timing of therapeutic interventions.
Read more
COVID-19 by itself remains biologically novel and not much is known about the role of novel coronavirus SARS-CoV-2 in cancer. Similar to other severe acute respiratory outbreaks (SARS-CoV, MERS-CoV), comorbidities such as hypertension and malignancy predispose COVID-19-positive patients to adverse clinical outcomes. Nevertheless, there exists no clear evidence that SARS-CoV-2 is causative, related to, or modulates cancer pathobiology! In this regard, further research is needed to improve the understanding of the biology of SARS-CoV-2 virus, its molecular connection to cancer, and the temporal features of SARS-CoV‐2-induced inflammatory response in relation to the timing of therapeutic interventions.
Read more
View: 1129 Time(s) |
Print: 441 Time(s) |
Email: 0 Time(s) |
0 Comment(s)
